Screener
Rigel Pharmaceuticals RIGL Debt Repayments
Debt Repayments at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermLinesOfCredit.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchases of short-term investments | (23,920) | (21,652) |
| Net cash used in investing activities | (7,975) | (10,552) |
| Financing activities | ||
| Principal payments of term loans | (7,500) | — |
| Net proceeds from issuance of common stock under equity plans | 321 | 484 |
| Repurchases of common stock in connection with employee tax withholding on RSU vesting | (3,740) | — |
| Net cash (used in) provided by financing activities | (10,919) | 484 |
| Net decrease in cash, cash equivalents and restricted cash | (16,169) | (10,961) |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's debt repayments?
- Rigel Pharmaceuticals (RIGL) reported debt repayments of $7.5M in Q1 2026.
- What does debt repayments mean?
- Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.
Ask your AI about Rigel Pharmaceuticals's debt repayments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude